Jacobs Levy Equity Management
NAUT icon

Jacobs Levy Equity Management’s Nautilus Biotechnolgy NAUT Stock Holding History

Jacobs Levy Equity Management’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-46,394
Closed -$180K – 1038
2026
Q1 		$180K Buy
+46,394
New +$114K ﹤0.01% 922
2025
Q4 		– Sell
-301,012
Closed -$254K – 1020
2025
Q3 		$254K Buy
301,012
+46,153
+18% +$33.9K ﹤0.01% 895
2025
Q2 		$185K Buy
254,859
+29,761
+13% +$22.4K ﹤0.01% 994
2025
Q1 		$194K Buy
+225,098
New +$335K ﹤0.01% 1029

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Jacobs Levy Equity Management's NAUT Position: Q2 2026 in Review

Jacobs Levy Equity Management sold out of Nautilus Biotechnolgy (NAUT) in Q2 2026, closing a stake of 46,394 shares — an estimated $180K sold.

Jacobs Levy Equity Management first reported a position in NAUT in Q1 2025 and held it in 4 quarters. The position peaked at $254K in Q3 2025. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • Jacobs Levy Equity Management reported no remaining Nautilus Biotechnolgy position as of Q2 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 46,394 Nautilus Biotechnolgy shares in Q2 2026, an estimated $180K.
  • Jacobs Levy Equity Management first reported a position in Nautilus Biotechnolgy in Q1 2025 and held it in 4 quarters.
  • Jacobs Levy Equity Management's Nautilus Biotechnolgy position peaked at $254K in Q3 2025.
  • 93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.